Hilary D Boyer
Overview
Explore the profile of Hilary D Boyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
132
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel P, Harmon S, Iseman R, Ludkowski O, Auman H, Hawley S, et al.
Mod Pathol
. 2023 Jun;
36(10):100241.
PMID: 37343766
Phosphatase and tensin homolog (PTEN) loss is associated with adverse outcomes in prostate cancer and can be measured via immunohistochemistry. The purpose of the study was to establish the clinical...
2.
Chan E, McKenney J, Hawley S, Corrigan D, Auman H, Newcomb L, et al.
Mod Pathol
. 2022 Feb;
35(8):1092-1100.
PMID: 35145197
Cribriform growth pattern is well-established as an adverse pathologic feature in prostate cancer. The literature suggests "large" cribriform glands associate with aggressive behavior; however, published studies use varying definitions for...
3.
McKenney J, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, et al.
Am J Surg Pathol
. 2016 Sep;
40(11):1439-1456.
PMID: 27635949
Histologic grading remains the gold standard for prognosis in prostate cancer, and assessment of Gleason score plays a critical role in active surveillance management. We sought to optimize the prognostic...
4.
Newcomb L, Thompson Jr I, Boyer H, Brooks J, Carroll P, Cooperberg M, et al.
J Urol
. 2015 Sep;
195(2):313-20.
PMID: 26327354
Purpose: Active surveillance represents a strategy to address the overtreatment of prostate cancer, yet uncertainty regarding individual patient outcomes remains a concern. We evaluated outcomes in a prospective multicenter study...